Literature DB >> 29922655

Changes of Intestinal Functions in Liver Cirrhosis.

Hiroshi Fukui1, Reiner Wiest2.   

Abstract

BACKGROUND: Understanding of the gut-liver axis is important for the up-to-date management of liver cirrhosis, and changes of intestinal functions form the core of this interesting research field.
SUMMARY: Most investigators noted small intestinal dysmotility in their patients with liver cirrhosis. Marked changes in the contraction pattern were observed in early manometric studies. The orocecal transit time, particularly small intestinal transit, has generally been reported to be prolonged, which has been demonstrated in multiple investigations to be related to the severity of the liver disease (e.g., Child-Pugh class), the presence of small intestinal bacterial overgrowth (SIBO) and hepatic encephalopathy (HE) as well as a history of spontaneous bacterial peritonitis. Bacteriologically proven SIBO in proximal jejunal aspiration has been reported to be present in up to 59% of cirrhotic patients and is associated with systemic endotoxemia. Clinical and experimental studies suggest that delayed small bowel transit in liver cirrhosis may lead to SIBO, which could contribute to the symptoms of abdominal pain and diarrhea. In addition to autonomic neuropathy, metabolic derangements and diabetic state, SIBO itself may delay intestinal transit in cirrhotic patients. Several studies, both from the West and the East, have shown that the gut microbiota is altered in cirrhotic patients and particularly those with HE. Further, a quantitative change in Bacteroides/Firmicutes ratio, with a prevalence of potentially pathogenic bacteria (e.g., Enterobacteriaceae) and reduction in specific commensals (e.g., Lachnospiraceae), has been described. Structural and functional changes in the intestinal mucosa that contribute to increases in intestinal permeability for bacteria and their products have been observed in patients with liver cirrhosis, which is considered as an important pathogenetic factor for several complications. The mechanism of intestinal barrier dysfunction in cirrhosis is multifactorial, including alcohol, portal hypertension (vascular congestion and dysregulation), endotoxemia, SIBO, local inflammation and, most likely, immunological factors and medications. KEY MESSAGES: This review summarizes major achievements regarding intestinal dysfunction in cirrhosis for future gastroenterology research. The question of whether this intestinal barrier dysfunction is accompanied and/or at least partly caused by structural and functional changes in the epithelial tight junction proteins is as yet unsolved. Development of new strategies to modulate gut-liver interaction is urgently needed.

Entities:  

Keywords:  Bacterial translocation; Endotoxemia; Intestinal hyperpermeability; Liver cirrhosis; Small intestinal bacterial overgrowth; Small intestinal dysmotility

Year:  2016        PMID: 29922655      PMCID: PMC5988129          DOI: 10.1159/000444436

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  158 in total

Review 1.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

2.  Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis.

Authors:  Tatsuhiro Tsujimoto; Hideto Kawaratani; Toshiyuki Kitazawa; Masahito Uemura; Hiroshi Fukui
Journal:  Dig Dis Sci       Date:  2012-02-25       Impact factor: 3.199

3.  Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology.

Authors:  Linda Chia-Hui Yu; Jin-Town Wang; Shu-Chen Wei; Yen-Hsuan Ni
Journal:  World J Gastrointest Pathophysiol       Date:  2012-02-15

Review 4.  Intestinal permeability: an overview.

Authors:  I Bjarnason; A MacPherson; D Hollander
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

5.  Intestinal permeability in liver cirrhosis: relationship with severe septic complications.

Authors:  B Campillo; P Pernet; P N Bories; J P Richardet; M Devanlay; C Aussel
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-07       Impact factor: 2.566

Review 6.  Gut-liver axis in alcoholic liver disease.

Authors:  Gyongyi Szabo
Journal:  Gastroenterology       Date:  2014-11-11       Impact factor: 22.682

7.  Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study.

Authors:  Ulrich Thalheimer; Fosca De Iorio; Franco Capra; Maria del Mar Lleo; Valeria Zuliani; Valentina Ghidini; Maria Carla Tafi; Greta Caburlotto; Micol Gennari; Andrew K Burroughs; Italo Vantini
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-10       Impact factor: 2.566

8.  Intestinal permeability is increased in patients with advanced cirrhosis.

Authors:  Sonia Pascual; José Such; Angel Esteban; Pedro Zapater; Juan A Casellas; José R Aparicio; Eva Girona; Ana Gutiérrez; Fernando Carnices; Jose M Palazón; Javier Sola-Vera; Miguel Pérez-Mateo
Journal:  Hepatogastroenterology       Date:  2003 Sep-Oct

9.  Gastric emptying time and the effect of cisapride in cirrhotic patients with autonomic neuropathy.

Authors:  Yuksel Gumurdulu; Zeynep Yapar; Abdullah Canataroglu; Ender Serin; Derya Gumurdulu; Mustafa Kibar; Salih Colakoglu
Journal:  J Clin Gastroenterol       Date:  2003-02       Impact factor: 3.062

10.  The outer mucus layer hosts a distinct intestinal microbial niche.

Authors:  Hai Li; Julien P Limenitakis; Tobias Fuhrer; Markus B Geuking; Melissa A Lawson; Madeleine Wyss; Sandrine Brugiroux; Irene Keller; Jamie A Macpherson; Sandra Rupp; Bettina Stolp; Jens V Stein; Bärbel Stecher; Uwe Sauer; Kathy D McCoy; Andrew J Macpherson
Journal:  Nat Commun       Date:  2015-09-22       Impact factor: 14.919

View more
  18 in total

1.  Low potassium disrupt intestinal barrier and result in bacterial translocation.

Authors:  Haishan Wu; Rong Huang; Jinjin Fan; Ning Luo; Xiao Yang
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

2.  Exercise and physical activity in cirrhosis: opportunities or perils.

Authors:  Annette Bellar; Nicole Welch; Srinivasan Dasarathy
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

Review 3.  Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Bruno Sangro; Stephen L Chan; Tim Meyer; María Reig; Anthony El-Khoueiry; Peter R Galle
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

Review 4.  The microbiota in cirrhosis and its role in hepatic decompensation.

Authors:  Jonel Trebicka; Jane Macnaughtan; Bernd Schnabl; Debbie L Shawcross; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 5.  Current Status and Prospects of Spontaneous Peritonitis in Patients with Cirrhosis.

Authors:  Yong-Tao Li; Jian-Rong Huang; Mei-Lian Peng
Journal:  Biomed Res Int       Date:  2020-07-06       Impact factor: 3.411

Review 6.  Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.

Authors:  Katharine Margaret Irvine; Isanka Ratnasekera; Elizabeth E Powell; David Arthur Hume
Journal:  Front Immunol       Date:  2019-02-25       Impact factor: 7.561

Review 7.  Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.

Authors:  Daniela Campion; Ilaria Giovo; Paola Ponzo; Giorgio M Saracco; Federico Balzola; Carlo Alessandria
Journal:  World J Hepatol       Date:  2019-06-27

Review 8.  Preclinical insights into the gut-skeletal muscle axis in chronic gastrointestinal diseases.

Authors:  Luise Ehlers; Karen Bannert; Sarah Rohde; Peggy Berlin; Johannes Reiner; Mats Wiese; Julia Doller; Markus M Lerch; Ali A Aghdassi; Fatuma Meyer; Luzia Valentini; Ottavia Agrifoglio; Cornelia C Metges; Georg Lamprecht; Robert Jaster
Journal:  J Cell Mol Med       Date:  2020-07-06       Impact factor: 5.310

Review 9.  Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment.

Authors:  Ramzi Hassouneh; Jasmohan S Bajaj
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

Review 10.  Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liver Cirrhosis.

Authors:  Fatuma Meyer; Karen Bannert; Mats Wiese; Susanne Esau; Lea F Sautter; Luise Ehlers; Ali A Aghdassi; Cornelia C Metges; Leif-A Garbe; Robert Jaster; Markus M Lerch; Georg Lamprecht; Luzia Valentini
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.